Welcome to our dedicated page for EVELO BIOSCIENCES news (Ticker: EVLO), a resource for investors and traders seeking the latest updates and insights on EVELO BIOSCIENCES stock.
Evelo Biosciences, Inc. (Nasdaq: EVLO) is a clinical-stage biotechnology company committed to transforming the lives of patients worldwide by developing innovative medicines known as monoclonal microbials. These therapies are orally administered and designed to modulate systemic immunology and biology by interacting directly with human cells in the gut.
Evelo’s groundbreaking approach leverages the small intestinal axis (SINTAX) to develop medicines that hold promise for a wide range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, and neuroinflammatory conditions, as well as cancer. The company's monoclonal microbials are poised to revolutionize traditional drug discovery and development by enhancing speed, reducing costs, and increasing the success rate of therapeutic outcomes.
Recent achievements at Evelo include the ongoing development of EDP2939, a next-generation product candidate for moderate psoriasis, which builds on the positive Phase 2 clinical data of its predecessor, EDP1815. Despite challenges in recent trials, Evelo remains dedicated to advancing its SINTAX platform and pursuing strategic alternatives for further development and potential partnerships.
Financially, Evelo has recently secured additional financing and restructured its debt, providing the resources needed to continue its clinical programs into 2024. The company aims to deliver therapies that are not only effective and safe but also affordable, addressing the unmet needs of millions of patients with inflammatory diseases.
Founded within VentureLabs® by Flagship Pioneering, Evelo Biosciences is a testament to innovative biotechnology with a mission to discover and develop transformative medicines for a wide array of conditions.
For more information, please visit www.evelobio.com or contact their investor and media relations teams at ir@evelobio.com and media@evelobio.com.
Evelo Biosciences (Nasdaq: EVLO) announced the appointment of Ayse Kocak as Head of International & Special Projects, effective July 12, 2021. Kocak will lead Evelo's international expansion and COVID-19 initiatives, collaborating with US Commercial leadership. She brings extensive experience from her previous roles, including CEO of Global Aesthetics Consolidated. Evelo granted Kocak options to purchase 250,000 shares of common stock at $13.90 each, vesting subject to various conditions. The company's product candidates target inflammatory diseases and cancer.
Evelo Biosciences, a clinical-stage biotechnology company, announced the appointment of Mark Plinio as Chief Commercial Officer on June 14, 2021. In conjunction with his hiring, Evelo granted him an option to purchase 250,000 shares at $16.34 each, reflecting the stock's closing price on the grant date. This option vests 25% after one year and the remainder in monthly installments over three years. Evelo develops orally delivered medicines targeting immune and neurological systems, with four candidates currently in clinical development for inflammatory diseases and cancer.
Evelo Biosciences (Nasdaq: EVLO) announced an inducement equity plan as it accelerates growth and prepares to expand its Leadership Team. Effective June 1, 2021, Luca Scavo took on the role of Chief Financial Officer, receiving options for 300,000 shares at $14.24 each and 4,545 restricted stock units. These grants follow the 2021 Employment Inducement Award Plan approved by the Board. Evelo is focused on developing orally delivered medicines targeting the immune, metabolic, and neurological systems, with four product candidates currently in development.
Evelo Biosciences (Nasdaq:EVLO) announced the appointment of Mark Plinio as Chief Commercial Officer, effective June 14, 2021. Plinio brings extensive experience from Ironwood Pharmaceuticals and Novartis where he managed successful product launches. His leadership is expected to play a critical role in advancing Evelo's SINTAX medicines and building its commercial capabilities as the company develops products like EDP1815 for inflammatory conditions. Evelo aims to improve patient care through its innovative approach to therapeutics.
Evelo Biosciences (Nasdaq:EVLO) announced its participation in three upcoming virtual investor conferences in June 2021. The events include: Jefferies Virtual Healthcare Conference on June 2 at 1:30 p.m. ET, JMP Securities Life Sciences Conference on June 16 at 1:00 p.m. ET, and Raymond James Human Health Innovation Conference on June 22 at 9:20 a.m. ET. Live audio webcasts will be available on their website, with replays accessible for 30 days post-event. Evelo is developing innovative orally delivered medicines targeting SINTAX, with four product candidates aimed at inflammatory diseases and cancer.
Evelo Biosciences (Nasdaq:EVLO) presented promising preclinical data for its anti-inflammatory candidate EDP2939 at the Virtual IMMUNOLOGY2021. The study revealed that EDP2939, an orally delivered extracellular vesicle, demonstrated significant systemic anti-inflammatory effects in mouse models without safety concerns. The company plans to initiate clinical development for EDP2939 in 2022, suggesting a potential new treatment modality for inflammatory diseases. The findings support the ongoing development of Evelo’s SINTAX medicines, leveraging the small intestinal axis for therapeutic benefits.
Evelo Biosciences (Nasdaq:EVLO) reported key updates from its Phase 1b trial of EDP1815, demonstrating significant efficacy in treating atopic dermatitis. The company strengthened its leadership team, appointing Luca Scavo as CFO and Julie H. McHugh to the Board. A strategic collaboration with Abdul Latif Jameel Health was announced to commercialize EDP1815 in select developing markets. Financially, Evelo showed a cash position of $124.6 million but reported a net loss of $28.2 million for Q1 2021, widening from the previous year. Management anticipates multiple clinical readouts over the next 18 months.
Evelo Biosciences (Nasdaq: EVLO) will host a conference call on April 29, 2021, at 8:30 a.m. ET to report its Q1 2021 financial results and discuss business highlights. The call can be accessed at 866-795-3242 for domestic and 409-937-8909 for international callers, using conference ID 5856668. Evelo is developing orally delivered medicines targeting the immune, metabolic, and neurological systems via SINTAX. It has four product candidates in development for inflammatory diseases and cancer.
Evelo Biosciences (Nasdaq: EVLO) presented late-breaking data on EDP1815 for atopic dermatitis at the ISAD conference. The Phase 1b trial showed EDP1815 was well tolerated, with no serious adverse events. Patients treated with EDP1815 achieved significant improvements in the Investigator Global Assessment (IGA) scores, outperforming placebo by 31% at day 70. The company plans to initiate a Phase 2 trial in Q3 2021, aiming to expand its oral treatment options for mild to moderate atopic dermatitis, addressing a critical unmet need.
Evelo Biosciences (Nasdaq: EVLO) announced key management appointments: Luca Scavo as Chief Financial Officer (CFO) effective June 1, 2021, and Julie H. McHugh to the Board of Directors immediately. Scavo, with over 25 years in biotechnology, previously served at Roche as CFO of its North American diagnostics division. McHugh brings 35 years of experience in the life sciences, having held executive roles at major companies including Johnson & Johnson. CEO Simba Gill emphasized their expertise will aid in advancing Evelo's clinical development and commercialization goals.
FAQ
What is the current stock price of EVELO BIOSCIENCES (EVLO)?
What is the market cap of EVELO BIOSCIENCES (EVLO)?
What does Evelo Biosciences specialize in?
What diseases are Evelo's medicines targeting?
What is the SINTAX platform?
What is EDP2939?
Who founded Evelo Biosciences?
Has Evelo secured financing recently?
What recent trials has Evelo conducted?
What is the mission of Evelo Biosciences?
How can I contact Evelo Biosciences for investor information?
Where can I find more information about Evelo Biosciences?
